Nektar Therapeutics Announces Q3 2026 Financial Results and Conference Call Schedule

Nektar Therapeutics to Release Q3 Financial Results

Nektar Therapeutics, a prominent biotechnology company listed on Nasdaq under the ticker NKTR, has announced its plans to unveil its financial results for the third quarter, which ended on September 30, 2026. The announcement is scheduled for November 12, 2026, following the conclusion of financial trading in the U.S. markets.

Howard Robin, the President and CEO of Nektar, will lead a conference call at 5:00 PM Eastern Time (2:00 PM Pacific Time) to discuss the results in detail. Investors and the media will have the opportunity to gain insights into the company's performance over the past quarter, as well as its future outlook.

Accessing the Conference Call

Those interested in participating in the conference call can find the link on both the Home Page and the Investors section of the Nektar Therapeutics website at Nektar Investor Relations. Moreover, a live audio-only webcast of the conference will be available, which will be accessible for replay through December 12, 2026. To ensure your participation, it is recommended to pre-register via the website to receive dial-in details and a unique PIN for accessing the call.

About Nektar Therapeutics

Founded in San Francisco, California, Nektar Therapeutics is recognized for its focus on developing innovative treatments that address immune dysfunction associated with autoimmune and chronic inflammatory diseases. Its lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-of-its-kind regulatory T cell stimulator. This promising candidate is currently under investigation for treating conditions like atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.

In addition to NKTR-358, Nektar has an exciting pipeline consisting of several programs, including preclinical antibody therapies targeting tumor necrosis factor, such as NKTR-0165 and NKTR-0166, and a modified CSF protein known as NKTR-422.

As the company gears up for the upcoming financial disclosures, many will be looking for updates regarding the progress of its clinical trials and any new developments in their research pipeline. The outcomes of such conferences often serve as an indicator for investors regarding the company's health and future direction.

For further information about Nektar Therapeutics, their product offerings, and their research initiatives, visit Nektar Therapeutics Official Site or follow them on LinkedIn for the latest updates on their work and achievements.